Pharvaris NV (FRA:9EN) Accumulated Depreciation : €-0.26 Mil (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Pharvaris NV Accumulated Depreciation?

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Pharvaris NV's quarterly accumulated depreciation increased from Sep. 2024 (€-0.18 Mil) to Dec. 2024 (€-0.22 Mil) and increased from Dec. 2024 (€-0.22 Mil) to Mar. 2025 (€-0.26 Mil).

Pharvaris NV's annual accumulated depreciation increased from Dec. 2022 (€-0.07 Mil) to Dec. 2023 (€-0.13 Mil) and increased from Dec. 2023 (€-0.13 Mil) to Dec. 2024 (€-0.22 Mil).

Pharvaris NV Accumulated Depreciation Historical Data

The historical data trend for Pharvaris NV's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharvaris NV Accumulated Depreciation Chart

Pharvaris NV Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accumulated Depreciation

Get a 7-Day Free Trial

-0.01

-0.03

-0.07

-0.13

-0.22

Pharvaris NV Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accumulated Depreciation	Get a 7-Day Free Trial															-0.14	-0.16	-0.18	-0.22	-0.26

Pharvaris NV Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

Pharvaris NV Accumulated Depreciation Related Terms

Thank you for viewing the detailed overview of Pharvaris NV's Accumulated Depreciation provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharvaris NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharvaris NV (FRA:9EN) » Definitions » Accumulated Depreciation

Comparable Companies

Traded in Other Exchanges

PHVS:USA

Address

Emmy Noetherweg 2, Leiden, NLD, 2333 BK

Website

https://www.pharvaris.com

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Pharvaris NV Headlines

No Headlines